changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience.
We’ve earned a strong reputation for our commitment to innovation. It’s what drives our partnership with clinicians, academics, and other companies.
Innovation is a continuous process at BTG. We start with the needs of patients and an in-depth knowledge of our customers. Whether it’s spotting opportunities to improve our existing products or identifying new unmet needs, we are constantly learning from our physician partners. These insights help inform our investments in product development, physician-led exploratory studies, and full scale clinical trials.
For example, our Innovation team has used unique chemistry to develop the first radiopaque embolic bead that allows physicians to treat their patients with vision, precision and assurance. Cleared in the US as LC Bead LUMI™ and approved in the EU as DC Bead LUMI™, the beads are intended to be used for the embolisation of hypervascular tumours and arteriovenous malformations. We’ve used the same visible bead platform to develop a brand new experimental drug-eluting bead which delivers a precise dose of a targeted agent to tumours and is now in early clinical trials.
It’s not just new products, we strive to continuously improve what we have already. We felt we could improve personalisation of dosing when treating liver cancer with TheraSphere® so we partnered with physicians and a specialist imaging software company to new make a new dosimetry planning tool which is now being trialled. The next generation of our EKOS® control unit is smaller and more portable, with a touch screen user interface, and increased power to control two catheters. Our pipeline projects have the potential to expand our Interventional Medicine portfolio and leverage our platform technologies, while helping specialist physicians.
We are also investing in clinical trials designed to expand the uses and geographic availability of our products, and to help demonstrate their value.
Our advantage is our dedication to finding unconventional solutions to complex medical problems, working with interventional physicians to secure patient benefit. In 2016/17 we invested £87.8 million in product innovation and development.
We will continue to focus on what comes next, because we believe in the transformative power of medical innovation to improve human health.
We are investing in clinical trials designed to expand the uses and geographic availability of our products, and to help demonstrate their value.
At BTG, we are exploring the synergy between our locoregional therapies (LRT) and other immunotherapeutics to help drive patients’ own immune system to fight cancer.
By delivering products that improve patient treatment, and that are valued by clinicians and payers, we will grow our business sustainably and deliver significant value to all our stakeholders.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com